Cardiovascular Risk Assessment In Metabolic Syndrome

The most prominent feature of metabolic syndrome (MS) is multiple cardiovascular risk factors such as type 2 diabetes mellitus, impaired glucose tolerance, hypertension, and disorder of lipid and central obesity, which often assembled with the same MS patient. Risk assessment of MS helps to form the basis for early interventions. Many algorithms, functions, and scores, such as Framingham CHD risk function (Framingham function) and Ischemic Cardiovascular Disease prediction function (ICVD function), have been generated with the aim of accurately predicting the probability of a subsequent cardiovascular event in individuals. Framingham function is recommended by the American Heart Association to assess the cardiovascular absolute risk of MS patients, for CHD over the next 10 years. Chinese National Eighth Five-year Research Plan established ICVD function for assessing risk of Ischemic Cardiovascular Disease over the next 10 years in Chinese. To assess Cardiovascular risk in Metabolic Syndrome, we have to find out which individual risk factor of those function are more availably, find out which algorithms is more fit to MS.Subjects and Methods:1. Subjects1461 subjects (male 740, female 721) were divided into 4 groups. 1) MS with type 2 diabetes mellitus(DMS,424); 2)MS without type 2 diabetes mellitus(NDMS,213); 3)patients without metabolic syndrome(include essential hypertension,349,and type 2 diabetes mellitus,259,total 608);4) normal control. The MS definition was suggested by NCEP-ATPⅢ(with 3 or more the following factors: SBP≥130 and(or) DBP≥85 mmHg; TG≥1.7 mmol/L, HDL-C < 1.04 mmol/L(man); HDL-C < 1.30 mmol/L(woman) , waist circumference>80cm(woman), waist circumference>90cm(man)). FPG:≥6.1 mmol/L。Participants were classified as having diabetes if they had either FPG≥7.0 mmol/l or 2hPG≥11.1 mmol/l, according to the ADA definition. Essential hypertension was defined as systolic blood pressure (SBP)≥140mm Hg and(or) diastolic blood pressure (DBP)≥90 mmHg,with the World Health Organization-International Society of Hypertension (WHO/ISH) 1999 guidelines.